Evaluation of Efficacy and Safety of the Dosage Adjustment of Aprovel® (Irbesartan) in Hypertensive Outpatients in Current Clinical Practice

Primary: * To evaluate the efficacy of two regimens of irbesartan in patients responding but not normalized at 6 weeks of treatment (schema N°1: maintenance 150 mg/day, schema n°2: 300 mg/day for 6 more weeks) Secondary: * To evaluate the percentage of patients with DBP \< 90 mmHg at 6 and 12 weeks * To evaluate the percentage of patients with SBP \< 140 mmHg at 6 and 12 weeks * To evaluate rate of adverse events during the study